

# Prospective feasibility and safety study of robotic-assisted radical prostatectomy with the new Toumai™ robotic system

|  |   |   |
|--|---|---|
| <b>Submission date</b><br>28/08/2025   | <b>Recruitment status</b><br>No longer recruiting | <input type="checkbox"/> Prospectively registered<br><input type="checkbox"/> Protocol                                  |
| <b>Registration date</b><br>01/09/2025 | <b>Overall study status</b><br>Completed          | <input type="checkbox"/> Statistical analysis plan<br><input type="checkbox"/> Results                                  |
| <b>Last Edited</b><br>01/09/2025       | <b>Condition category</b><br>Cancer               | <input type="checkbox"/> Individual participant data<br><input checked="" type="checkbox"/> Record updated in last year |

## Plain English summary of protocol

### Background and study aims

Transitioning to a new robotic platform presents regulatory, logistical, and financial challenges. The Toumai™ (MicroPort® MedBot™) system has received European CE mark approval for urology, yet clinical experience outside China is limited. This study aims to assess the feasibility and safety of robot-assisted radical prostatectomy (RARP) using the Toumai™ robotic system in a tertiary center.

### Who can participate?

Patients aged 18 years and over with localized prostate cancer who want to be treated with robotic radical prostatectomy

### What does the study involve?

Patients are treated with robot-assisted radical prostatectomy using the Toumai™ MT1000 platform.

### What are the possible benefits and risks of participating?

Prostate cancer surgery carries specific risks but participating in the study does not increase those risks as it is a validated technology with CE mark approval.

### Where is the study run from?

Clinica Alemana de Santiago (Chile)

### When is the study starting and how long is it expected to run for?

December 2024 to August 2025

### Who is funding the study?

Clínica Alemana de Santiago (Chile)

### Who is the main contact?

Hugo Otaola, [Hugotaolarca@hotmail.com](mailto:Hugotaolarca@hotmail.com)

# Contact information

## Type(s)

Public, Scientific, Principal investigator

## Contact name

Dr Hugo Otaola Arca

## ORCID ID

<https://orcid.org/0000-0003-4952-2283>

## Contact details

Avda. Manquehue Norte 1410

Piso 12

Vitacura

Región Metropolitana

Santiago

Chile

7650568

+56 (0)2 2210 1111

hotaola@alemana.cl

# Additional identifiers

## Clinical Trials Information System (CTIS)

Nil known

## Protocol serial number

ID 1052

# Study information

## Scientific Title

Introducing the Toumai™ System for robot-assisted radical prostatectomy: a prospective feasibility and safety study in a tertiary care center (TouRARP)

## Acronym

TouRARP

## Study objectives

Assess the feasibility and safety of robot-assisted radical prostatectomy (RARP) using the Toumai™ robotic system in a tertiary center. Furthermore, the researchers aimed to describe its key features to guide centers considering this technology

## Ethics approval required

Ethics approval not required

## Ethics approval(s)

**Study design**

Prospective single-center case series

**Primary study design**

Observational

**Study type(s)**

Treatment

**Health condition(s) or problem(s) studied**

Prostate cancer

**Interventions**

Robot-assisted radical prostatectomy with Toumai™ robotic system

**Intervention Type**

Device

**Phase**

Not Applicable

**Drug/device/biological/vaccine name(s)**

Toumai™ robotic system (MT 1000)

**Primary outcome(s)**

1. Feasibility, defined as the successful completion of surgical procedures without needing to convert to conventional techniques at the end of surgery
2. Safety evaluated through documentation of intraoperative or postoperative complications at 1 month of follow-up

**Key secondary outcome(s)**

Perioperative variables associated with this new robotic platform, measured using the Clavien-Dindo classification at 1 month of follow-up

**Completion date**

31/08/2025

**Eligibility****Key inclusion criteria**

Localized prostate cancer

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Adult

**Lower age limit**

18 years

**Sex**

Male

**Total final enrolment**

50

**Key exclusion criteria**

Patients for whom all perioperative information was not available were excluded from the analysis

**Date of first enrolment**

04/12/2024

**Date of final enrolment**

28/08/2025

## Locations

**Countries of recruitment**

Chile

**Study participating centre**

**Clínica Alemana**

Av. Manquehue Nte. 1410

Vitacura

Región Metropolitana

Santiago

Chile

7650568

## Sponsor information

**Organisation**

Clínica Alemana

**ROR**

<https://ror.org/028ynny55>

# Funder(s)

## Funder type

Hospital/treatment centre

## Funder Name

Clínica Alemana de Santiago

## Alternative Name(s)

Clínica Alemana

## Funding Body Type

Private sector organisation

## Funding Body Subtype

Other non-profit organizations

## Location

Spain

# Results and Publications

## Individual participant data (IPD) sharing plan

Datasets generated during de current study will be available upon request from Hugo Otaola-Arca (hugotaolarca@hotmail.com)

## IPD sharing plan summary

Available on request